Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04456296 · ClinicalTrials.gov registry record · Phase 4
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
A Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 673
- Enrollment target
NCT04456296: Completed Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT04456296 is a Phase 4 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 673 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04456296, a Phase 4 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 673 participants
- Enrollment target
Study Summary
Testosterone is the principal androgen produced by the male testes. Male Hypogonadism is the result of inadequate production of testosterone by the Leydig cells of the testes and is reflected by total serum concentrations of testosterone of \< 300 nanograms (ng)/deciliters (dL), with no discernible diurnal pattern. The etiology of hypogonadism may be primary or secondary. The treatment of males with primary, and in some cases, secondary hypogonadism includes administration of testosterone. Testim® and Fortesta® are topical gels that when applied daily help to increase the total testosterone levels in the blood through skin absorption. Aveed® is an injectable form of testosterone treatment and participants randomized to this treatment arm will receive 3 injections over the course of 16 weeks. This study is designed to evaluate the effect on blood pressure of approved testosterone products (Testim®, Fortesta®, and Aveed®) after 16 weeks of therapy using 24-hour ambulatory blood pressure to reveal shifts in blood pressure levels.
Interventions
- DRUG Fortesta
- DRUG Aveed Injectable Product
- DRUG Testim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 673 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2023-07-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04456296
The ClinicalTrials.gov registry entry for NCT04456296 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 673 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fortesta is the first listed.
NCT04456296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04456296 about?
NCT04456296 is a clinical study titled "A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism". Testosterone is the principal androgen produced by the male testes. Male Hypogonadism is the result of inadequate production of testosterone by the Leydig cells of the testes and is reflected by total serum concentrations of testosterone of \< 300 nanograms (ng)/deciliters (dL), with no discernible ...
What is the current status of trial NCT04456296?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 673 participants. The study started on 2020-06-30. Estimated completion is 2023-07-12.
What interventions are being tested in trial NCT04456296?
The interventions under investigation include: Fortesta (DRUG), Aveed Injectable Product (DRUG), Testim (DRUG).
Who is sponsoring clinical trial NCT04456296?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.